Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): a subgroup analysis from the phase 3 ARROW study

被引：0
|
作者：
Mateos, Maria-Victoria [1 ]
Ludwig, Heinz [2 ]
Kumar, Shaji [3 ]
Rosenbaum, Cara [4 ]
Huang, Mei [5 ]
Goldrick, Amanda [5 ]
Blaedel, Julie [5 ]
Dimopoulos, Meletios A. [6 ]
机构：
[1] Univ Hosp Salamanca IBSAL, Salamanca, Spain
[2] Wilhelminenspital Stadt Wien, Wilhelminen Canc Res Inst, Vienna, Austria
[3] Mayo Clin, Rochester, MN USA
[4] Weill Cornell Med, New York, NY USA
[5] Amgen Inc, Thousand Oaks, CA 91320 USA
[6] Univ Athens, Sch Med, Athens, Greece
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
carfilzomib; frailty; Relapsed Refractory MM;
D O I：
10.1016/j.clml.2019.09.047
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OAB-046
引用
收藏
页码：E31 / E32
页数：2
相关论文
共 50 条
  • [31] Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin®) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study
    Horikawa, Reiko
    Tanaka, Toshiaki
    Hasegawa, Yukihiro
    Yorifuji, Tohru
    Ng, David
    Rosenfeld, Ron G.
    Hoshino, Yuko
    Okayama, Akifumi
    Shima, Daisuke
    Gomez, Roy
    Pastrak, Aleksandra
    Castellanos, Orlando
    HORMONE RESEARCH IN PAEDIATRICS, 2022, 95 (03): : 275 - 285
  • [32] Efficacy and safety of once-weekly insulin icodec in type 2 diabetes: A meta-analysis of ONWARDS phase 3 randomized controlled trials
    Shetty, Sahana
    Suvarna, Renuka
    DIABETES OBESITY & METABOLISM, 2024, 26 (03): : 1069 - 1081
  • [33] Assessment of Minimal Residual Disease in a Phase 1b Study of Once-Weekly Carfilzomib Combined with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma
    Landgren, Ola
    Alsina, Melissa
    Biran, Noa
    Vesole, David H.
    Wallace, Paul K.
    Fang, Belle
    Arnold, Gregory
    Kimball, Amy
    Siegel, David S.
    BLOOD, 2020, 136
  • [34] Efficacy and safety of PEX168, a novel once-weekly GLP-1 RA, for monotherapy in patients with type 2 diabetes: a phase 3a study
    Yang, W.
    Ji, Q.
    Shan, Z.
    Zhang, Q.
    Li, Y.
    Li, X.
    Qin, G.
    DIABETOLOGIA, 2019, 62 : S367 - S367
  • [35] Efficacy and Safety in Chinese T2D Patients Discontinued from OAM to Once-Weekly Dulaglutide Monotherapy
    Li, Yanbing
    Zhang, Bin
    Liu, Siying
    DIABETES, 2020, 69
  • [36] Safety and efficacy of weekly docetaxe in frail and/or elderly patients with metastatic breast cancer: a phase II study
    D'hondt, R
    Paridaens, R
    Wildiers, H
    Pauwelyn, K
    Thomas, J
    Dumez, H
    Van Osterom, AT
    ANTI-CANCER DRUGS, 2004, 15 (04) : 341 - 346
  • [37] Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study
    Mateos, Maria
    Gavriatopoulou, Maria
    Facon, Thierry
    Auner, Holger W.
    Leleu, Xavier
    Hajek, Roman
    Dimopoulos, Meletios A.
    Delimpasi, Sosana
    Simonova, Maryana
    Spicka, Ivan
    Pour, Ludek
    Kryachok, Irina
    Pylypenko, Halyna
    Doronin, Vadim A.
    Usenko, Ganna
    Benjamin, Reuben
    Dolai, Tuphan Kanti
    Sinha, Dinesh Kumar
    Venner, Christopher P.
    Garg, Mamta
    Stevens, Don A.
    Quach, Hang
    Jagannath, Sundar
    Moreau, Philippe
    Levy, Moshe
    Badros, Ashraf Z.
    Anderson, Larry D., Jr.
    Bahlis, Nizar J.
    Cavo, Michele
    Chai, Yi
    Arazy, Melina
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    Richardson, Paul G.
    Grosicki, Sebastian
    BLOOD, 2020, 136
  • [38] Once-weekly (70 mg/m2) vs twice-weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, ARROW, and CHAMPION-1 trials
    Moreau, Philippe
    Stewart, Keith A.
    Dimopoulos, Meletios
    Siegel, David
    Facon, Thierry
    Berenson, James
    Raje, Noopur
    Berdeja, Jesus G.
    Orlowski, Robert Z.
    Yang, Hui
    Ma, Haijun
    Klippel, Zandra
    Zahlten-Kumeli, Anita
    Mezzi, Khalid
    Iskander, Karim
    Mateos, Maria-Victoria
    CANCER MEDICINE, 2020, 9 (09): : 2989 - 2996
  • [39] Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study
    Hitoshi Ishii
    Yukiko Onishi
    Tomonori Oura
    Masakazu Takeuchi
    Diabetes Therapy, 2020, 11 : 133 - 145
  • [40] Cardiovascular safety and efficacy of exenatide once-weekly in patients with moderate renal dysfunction in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
    Hernandez, A. F.
    Bethel, M. A.
    Bakris, G. L.
    Merrill, P.
    Gustavson, S. M.
    Katona, B. G.
    Ohman, P.
    Lokhnygina, Y.
    Mentz, R. J.
    Holman, R. R.
    DIABETOLOGIA, 2018, 61 : S38 - S38
12345